Astellas Pharma Inc - Tokyo-based pharmaceutical company - Says findings from a phase three Skylight one clinical trial examining the safety and efficacy of fezolinetant met all four co-primary endpoints. Fezolinetant is an investigational oral, non-hormonal compound being studied for the treatment of moderate to severe symptoms associated with menopause such as hot flashes and night sweats. Results from the trial demonstrated a significant reduction in the frequency and severity of moderate to severe symptoms at weeks four and twelve against the placebo.
Current stock price: JPY1,954.50
12-month change: up 16%
By Heather Rydings; heatherrydings@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.